BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33300554)

  • 1. Epigenetically regulated gene expression profiles reveal four molecular subtypes with prognostic and therapeutic implications in colorectal cancer.
    Wang X; Liu J; Wang D; Feng M; Wu X
    Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33300554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer.
    Lin BB; Lei HQ; Xiong HY; Fu X; Shi F; Yang XW; Yang YF; Liao GL; Feng YP; Jiang DG; Pang J
    Comput Struct Biotechnol J; 2021; 19():4941-4953. PubMed ID: 34527198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer.
    Weng S; Li M; Deng J; Xu H; Ren Y; Zhou Z; Wang L; Zhang Y; Xing Z; Li L; Liu Z; Han X
    Clin Epigenetics; 2023 Apr; 15(1):64. PubMed ID: 37061743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.
    Weisenberger DJ; Liang G; Lenz HJ
    Oncogene; 2018 Feb; 37(5):566-577. PubMed ID: 28991233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer.
    Budinska E; Popovici V; Tejpar S; D'Ario G; Lapique N; Sikora KO; Di Narzo AF; Yan P; Hodgson JG; Weinrich S; Bosman F; Roth A; Delorenzi M
    J Pathol; 2013 Sep; 231(1):63-76. PubMed ID: 23836465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer.
    Zhang H; Dong S; Feng J
    J Cell Biochem; 2019 Jun; 120(6):10767-10776. PubMed ID: 30672027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype.
    Fessler E; Jansen M; De Sousa E Melo F; Zhao L; Prasetyanti PR; Rodermond H; Kandimalla R; Linnekamp JF; Franitza M; van Hooff SR; de Jong JH; Oppeneer SC; van Noesel CJ; Dekker E; Stassi G; Wang X; Medema JP; Vermeulen L
    Oncogene; 2016 Nov; 35(46):6026-6037. PubMed ID: 27157610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Coppedè F; Lopomo A; Spisni R; Migliore L
    World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation.
    Coppedè F
    Cancer Lett; 2014 Jan; 342(2):238-47. PubMed ID: 22202641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 15. Genome-scale analysis of aberrant DNA methylation in colorectal cancer.
    Hinoue T; Weisenberger DJ; Lange CP; Shen H; Byun HM; Van Den Berg D; Malik S; Pan F; Noushmehr H; van Dijk CM; Tollenaar RA; Laird PW
    Genome Res; 2012 Feb; 22(2):271-82. PubMed ID: 21659424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas.
    Fennell L; Dumenil T; Wockner L; Hartel G; Nones K; Bond C; Borowsky J; Liu C; McKeone D; Bowdler L; Montgomery G; Klein K; Hoffmann I; Patch AM; Kazakoff S; Pearson J; Waddell N; Wirapati P; Lochhead P; Imamura Y; Ogino S; Shao R; Tejpar S; Leggett B; Whitehall V
    Cell Mol Gastroenterol Hepatol; 2019; 8(2):269-290. PubMed ID: 30954552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of aberrant DNA methylation during colorectal cancer development.
    Sakai E; Nakajima A; Kaneda A
    World J Gastroenterol; 2014 Jan; 20(4):978-87. PubMed ID: 24574770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.